USP9X and triple-negative breast carcinoma: For example, in triple-negative breast cancer (TNBC), USP9X deubiquitinates and stabilizes PPP1R14B, leading to PPP1R14B overexpression in TNBC tissues, decreasing STMN1-mediated α-microtubule protein acetylation and microtubule stability, and promoting cell cycle progression, leading to paclitaxel resistance in TNBC cells [40].